TherapeuticsMD, Inc. (:TXMD) Volume Spiking Mid-session

Oppenheimer Holdings, Inc. cut shares of TherapeuticsMD from an outperform rating to a market perform rating and set a $12.00 price target on the stock.in a report on Tuesday, May 9th. NY now owns 103,048 shares of the company's stock valued at $742,000 after buying an additional 3,472 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. increased its position in TherapeuticsMD by 20.3% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 28,730 shares of the company's stock valued at $207,000 after buying an additional 10,330 shares during the period. Stifel Financial Corp raised its stake in shares of TherapeuticsMD by 125.4% in the first quarter. Stifel Financial Corp now owns 429,362 shares of the company's stock valued at $3,091,000 after buying an additional 238,885 shares during the last quarter. JPMorgan Chase & Co. raised its position in shares of TherapeuticsMD by 2.5% in the first quarter. JPMorgan Chase & Co. now owns 13,725,853 shares of the company's stock worth $98,827,000 after buying an additional 329,245 shares during the last quarter. Guggenheim Capital LLC increased its position in TherapeuticsMD by 135.9% in the fourth quarter. Greenwood Capital Associates LLC now owns 20,309 shares of the company's stock valued at $146,000 after buying an additional 3,022 shares during the last quarter.

Session activity on TherapeuticsMD, Inc.(:TXMD) shares bumps the stock on today's most active list. The company had a trading volume of 3,982,203 shares. Company shares have been seen trading -36.59% off of the 52 week high and 50.29% away from the 52 week low. The company's 50-day moving average price is $4.62 and its 200 day moving average price is $5.62. The stock's market capitalization is $1.15 billion.

A number of institutional investors have recently bought and sold shares of TXMD. If you are viewing this story on another domain, it was illegally stolen and reposted in violation of US & global trademark & copyright laws. The original version of this story can be viewed at https://www.chaffeybreeze.com/2017/07/17/therapeuticsmd-inc-nasdaqtxmd-stock-rating-upgraded-by-cibc.html.

TherapeuticsMD Inc (NASDAQ:TXMD) has received an average recommendation of "Buy" from the six ratings firms that are covering the stock, Marketbeat reports. (NASDAQ:EBAY) to report $ 0.48 EPS and has got OUTPERFORM rating from 8 of Thomson Reuters analysts and 2 analyst (s) given UNDERPERFORM rating. Stifel Nicolaus reissued a buy rating and set a $20.00 price target on shares of TherapeuticsMD in a research note on Monday, April 24th. Cantor Fitzgerald reiterated an "overweight" rating on shares of TherapeuticsMD in a research report on Monday, April 17th. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company's stock. The company has a consensus rating of Buy and a consensus target price of $18.00.